Technical Analysis for BGNE - BeiGene, Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 319.39 | -0.19% | -0.61 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Flat | Down |
| Historical BGNE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 50 DMA Support | Bullish | -0.19% | |
| Stochastic Reached Oversold | Weakness | -4.63% | |
| Oversold Stochastic | Weakness | -4.63% | |
| 50 DMA Support | Bullish | -3.93% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 50 DMA Support | about 11 hours ago | |
| 2x Volume Pace | about 11 hours ago | |
| 1.5x Volume Pace | about 11 hours ago | |
| Down 1% | about 11 hours ago | |
| Up 2% | about 11 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 09/27/2019
BeiGene, Ltd. Description
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancers Monoclonal Antibodies Monoclonal Antibody Lymphoma Oncogenes Protein Kinase Kras Humanized Antibody Ras Subfamily Braf Bruton's Tyrosine Kinase Rp1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 388.97 |
| 52 Week Low | 118.55 |
| Average Volume | 325,107 |
| 200-Day Moving Average | 257.41 |
| 50-Day Moving Average | 318.81 |
| 20-Day Moving Average | 353.87 |
| 10-Day Moving Average | 339.56 |
| Average True Range | 16.60 |
| ADX | 25.5 |
| +DI | 19.69 |
| -DI | 32.94 |
| Chandelier Exit (Long, 3 ATRs ) | 339.16 |
| Chandelier Exit (Short, 3 ATRs ) | 360.51 |
| Upper Bollinger Band | 395.09 |
| Lower Bollinger Band | 312.65 |
| Percent B (%b) | 0.08 |
| BandWidth | 23.30 |
| MACD Line | -0.62 |
| MACD Signal Line | 7.30 |
| MACD Histogram | -7.9223 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 337.35 | ||||
| Resistance 3 (R3) | 337.88 | 332.42 | 334.35 | ||
| Resistance 2 (R2) | 332.42 | 327.85 | 332.16 | 333.35 | |
| Resistance 1 (R1) | 325.91 | 325.03 | 329.17 | 325.38 | 332.36 |
| Pivot Point | 320.45 | 320.45 | 322.08 | 320.19 | 320.45 |
| Support 1 (S1) | 313.94 | 315.88 | 317.20 | 313.41 | 306.42 |
| Support 2 (S2) | 308.48 | 313.06 | 308.22 | 305.43 | |
| Support 3 (S3) | 301.97 | 308.48 | 304.43 | ||
| Support 4 (S4) | 301.44 |
